BR112022024404A2 - Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus - Google Patents

Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Info

Publication number
BR112022024404A2
BR112022024404A2 BR112022024404A BR112022024404A BR112022024404A2 BR 112022024404 A2 BR112022024404 A2 BR 112022024404A2 BR 112022024404 A BR112022024404 A BR 112022024404A BR 112022024404 A BR112022024404 A BR 112022024404A BR 112022024404 A2 BR112022024404 A2 BR 112022024404A2
Authority
BR
Brazil
Prior art keywords
particle
cancer
treatment
arenavirus
picv
Prior art date
Application number
BR112022024404A
Other languages
English (en)
Portuguese (pt)
Inventor
Matushansky Igor
Hwang Andy
Katchar Kianoosh
Edwards Donna
LAUTERBACH Henning
Schwendinger Michael
Orlinger Klaus
Schmidt Sarah
Berka Ursula
Iacobucci Corinne
Schlienger Katia
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of BR112022024404A2 publication Critical patent/BR112022024404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022024404A 2020-05-29 2021-05-12 Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus BR112022024404A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063032362P 2020-05-29 2020-05-29
US202163173155P 2021-04-09 2021-04-09
US202163175842P 2021-04-16 2021-04-16
PCT/EP2021/062728 WO2021239471A1 (en) 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors

Publications (1)

Publication Number Publication Date
BR112022024404A2 true BR112022024404A2 (pt) 2023-02-07

Family

ID=75914543

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024404A BR112022024404A2 (pt) 2020-05-29 2021-05-12 Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Country Status (12)

Country Link
US (1) US20230346906A1 (enExample)
EP (1) EP4157342A1 (enExample)
JP (1) JP2023527083A (enExample)
KR (1) KR20230046278A (enExample)
AU (1) AU2021282287A1 (enExample)
BR (1) BR112022024404A2 (enExample)
CA (1) CA3184791A1 (enExample)
CR (1) CR20220602A (enExample)
IL (1) IL298420A (enExample)
MX (1) MX2022014725A (enExample)
PE (1) PE20240647A1 (enExample)
WO (1) WO2021239471A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP4475879A1 (en) * 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
IL262963B2 (en) 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒

Also Published As

Publication number Publication date
CR20220602A (es) 2023-05-16
EP4157342A1 (en) 2023-04-05
MX2022014725A (es) 2023-02-09
WO2021239471A9 (en) 2022-01-13
AU2021282287A1 (en) 2023-01-05
US20230346906A1 (en) 2023-11-02
PE20240647A1 (es) 2024-04-04
KR20230046278A (ko) 2023-04-05
CA3184791A1 (en) 2021-12-02
JP2023527083A (ja) 2023-06-26
WO2021239471A1 (en) 2021-12-02
IL298420A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2024010999A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
MX2021001883A (es) Virus recombinantes del mixoma y usos de los mismos.
EP4141111A4 (en) ONCOLYTIC VIRUS VACCINE AND DRUG FOR THE TREATMENT OF TUMORS BY COMBINATION OF ONCOLYTIC VIRUS VACCINE WITH IMMUNE CELLS
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
MX2022014725A (es) Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus.
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MY196026A (en) Stem Cell Conditioned Media for Clinical and Cosmetic Applications
PH12019502522A1 (en) Oncolytic virus and method
BR112014012491A2 (pt) partícula tipo vírus, método para produzir uma partícula tipo vírus, método para impedir ou tratar a infecção pelo hpv ou câncer cervical em um indivíduo, uso de uma partícula tipo vírus, e, composição farmacêutica
SG10201811190SA (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
WO2020014591A8 (en) Apmv and uses thereof for the treatment of cancer
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
PE20221768A1 (es) Inhibidores de egfr
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
NZ603442A (en) Treatment of proliferative diseases
AR093908A1 (es) Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
BR112022019334A2 (pt) Método para produzir um genoma viral interferente defeituoso, genomas virais interferentes defeituosos, partícula interferente defeituosa, método de tratamento de uma infecção viral, genoma interferente defeituoso, composição farmacêutica, imunogênica ou terapêutica, vacina, uso, polinucleotídeo, vetor de expressão ou plasmídeo e linhagem de células
WO2007064900A3 (en) Treatment of lesions or imperfections in mammalian skin or near-skin tissues or in or near other anatomic surfaces
WO2021011844A3 (en) Combination cancer therapy agents and methods